526 related articles for article (PubMed ID: 16218777)
41. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
Guerrero J; Santibañez JF; González A; Martínez J
Exp Cell Res; 2004 Jan; 292(1):201-8. PubMed ID: 14720519
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
43. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
44. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
45. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
46. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
47. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
[TBL] [Abstract][Full Text] [Related]
48. Participation of urokinase-type plasminogen activator receptor in the clearance of fibrin from the lung.
Hattori N; Sisson TH; Xu Y; Desai TJ; Simon RH
Am J Physiol; 1999 Sep; 277(3):L573-9. PubMed ID: 10484465
[TBL] [Abstract][Full Text] [Related]
49. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P
J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526
[TBL] [Abstract][Full Text] [Related]
50. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
51. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor.
Hu XW; Duan HF; Gao LH; Pan SY; Li YM; Xi Y; Zhao SR; Yin L; Li JF; Chen HP; Wu CT
Cancer Biol Ther; 2008 May; 7(5):651-9. PubMed ID: 18245952
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Kobayashi H; Gotoh J; Hirashima Y; Fujie M; Sugino D; Terao T
J Biol Chem; 1995 Apr; 270(14):8361-6. PubMed ID: 7713945
[TBL] [Abstract][Full Text] [Related]
54. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
[TBL] [Abstract][Full Text] [Related]
55. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
56. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C; Merton RE; Fabregas P; Felez J
Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
[TBL] [Abstract][Full Text] [Related]
57. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
Ossowski L; Clunie G; Masucci MT; Blasi F
J Cell Biol; 1991 Nov; 115(4):1107-12. PubMed ID: 1659573
[TBL] [Abstract][Full Text] [Related]
58. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
59. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
Jo M; Thomas KS; Wu L; Gonias SL
J Biol Chem; 2003 Nov; 278(47):46692-8. PubMed ID: 12963722
[TBL] [Abstract][Full Text] [Related]
60. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
